secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-07-29T20:05:43+00:00
Accession:  0001193125-26-323651
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics exchanges 18M shares with RA Capital for pre-funded warrants
--------------------------------------------------------------------------------

- RA Capital exchanged 18,030,000 common shares for pre-funded warrants with $0.001 exercise price.
- Warrants are immediately exercisable, no expiration, with 9.99% beneficial ownership blocker (can increase to 19.99%).
- Issued under Section 3(a)(9) exemption from registration; no new cash raised.
- Exchange reduces outstanding shares but introduces potential dilution upon warrant exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/0001193125-26-323651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/d78217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-323651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer